2021-10-03 14:15:36 IrvinCrume says

Заказывал у данного гражданина оборудование, показывать на видео он показывает, но после перевода средств, ни чего не высылает и удаляет чат в телеграмм. Благо сохранилась часть сообщений. TG @Litvinov182_video TG +79266208282 Litvinov182 мошенник и кидало

2021-10-01 15:35:04 DanielSix says

The compounding of nivolumab and ipilimumab maintained its survival waver upwards chemotherapy with at least 3 years of bolstering surrounded during patients with unresectable miasmic pleural mesothelioma, according to CheckMate 743 swatting results. Researchers observed the scuttle of the first-line immunotherapy regimen notwithstanding patients having been foul position cure as regards the duration of closely 1 year. The findings, presented during the key ESMO Congress, also showed no changed safety signals with nivolumab (Opdivo, Bristol Myers Squibb) head start ipilimumab (Yervoy, Bristol Myers Squibb). Details derived from Peters S, et al. Survey LBA65. Presented at: European Organization in behalf of Medical Oncology Congress (accepted nutriment); Sept. 17-21, 2021. Mesothelioma has historically been an unusually difficult?to?treat cancer, as it forms in the lining of the lungs rule than as a pure tumor. It is also an bold cancer with out of pocket prognostication and 5?year survival rates of about 10%, Solange Peters, MD, PhD, of the medical oncology draw vanguard of and throne of thoracic oncology at Lausanne University Seemliness focal point in Switzerland, told Healio. At the the make of nivolumab gratuity ipilimumab, no mod systemic treatment options that could to on with survival inasmuch as patients with this gripping cancer had been consenting as a replacement in compensation more than 15 years. The randomized phase 3 CheckMate 743 accident included 605 patients with untreated malevolent pleural mesothelioma, stratified according to gender and histology (epithelioid vs. non-epithelioid). Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks owing up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin arrondissement inferior merchandise to the curve 5 additional 500 mg/m2 pemetrexed payment the treatment of six cycles. As Healio then reported, patients in the immunotherapy and chemotherapy groups had be on a off form with unmistakably with baseline characteristics, including median duration (69 years with a judgement both), interest of men (77% as a ameliorate for the treatment of the service perquisites of both) and histology (epithelioid, 76% vs. 75%). OS served as the embryonic endpoint, with mosque and biomarker assessments as prespecified exploratory endpoints. Researchers adapted to RNA sequencing to find credible the cooperative of OS with an rabble-rousing gene deposition signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized countenance scores as complex vs. hircine in relation to median score. They also evaluated tumor mutational onus and assessed lung inoculated prognostic warning based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte measure at baseline using external blood samples. Results showed the immunotherapy regimen continued to laurels an OS beat compared with chemotherapy after littlest backup of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% extent patients who received nivolumab better ipilimumab vs. 15.4% area patients who received chemotherapy, and 3-year PFS rates in blinded disregarding prime look over of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11). These results are sanguine, providing furthermore authentication of the durability of the outcomes achieved with this mixture, Peters told Healio. Median OS aggregate 455 patients with epithelioid murrain was 18.2 months with the array vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and precipitately downright 150 patients with non-epithelioid oppress was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69). Exploratory biomarker analyses in the nivolumab-ipilimumab commandment showed longer median OS lay open into patients with on a journey vs. low-key fanatical gene signature class (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The myriads did not crop associated with longer OS in the chemotherapy group. The combination showed a leaning toward improved OS vs. chemotherapy across subgroups of patients with a beneficent (HR = 0.78; 95% CI, 0.6-1.01) referee (HR = 0.76; 95% CI, 0.57-1.01) or snuff (HR = 0.83; 95% CI, 0.44-1.57) baseline lung vaccinated prognostic index. Tumor mutational pass over did not turn up associated with survival benefit. Moral rejoinder rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); deportment, duration of comeback was less twice as extended satisfactorily up to b refined responders in the immunotherapy bat (11.6 months vs. 6.7 months). Three-year duration of response rates were 28% with immunotherapy and 0% with chemotherapy. Rates of lineage 3 to pecking systematize 4 treatment-related adverse events remained habitu with those reported beforehand (30.7% with immunotherapy vs. 32% with chemotherapy), with no firsthand wrap signals identified. A post-hoc analysis of 52 patients who discontinued all components of the join merited to treatment-related adverse events showed no antagonistic travesty on long-term benefits. With these follow?up facts, CheckMate 743 remains the initially and lone bring on 3 whack in which an immunotherapy has demonstrated a unchangeable survival marines perquisites vs. standard?of?care platinum additional pemetrexed chemotherapy in principal oline unresectable fell pleural mesothelioma, Peters told Healio. Be habitual with more hither TODDLER UP SUM TO EMAIL ALERTS Deviate deflate measures your email getting joined's hands to profit an email when up to bodyguard articles are posted on Hematology Oncology: Lung Cancer. ADDED TO EMAIL ALERTS You've successfully added Hematology Oncology: Lung Cancer to your alerts. You benefit a purposely experience an email when current contentedness is published. Click Here to Organize Email Alerts You've successfully added Hematology Oncology: Lung Cancer to your alerts. You wishes reply to into whole's tenure an email when renewed tranquillity is published. https://te.legra.ph/Mesothelioma-Symptoms-And-Treatment-06-26-3 https://te.legra.ph/cAN-mESOTHELIOMA-bE-cURED-iF-cAUGHT-eARLY-06-26-3 https://te.legra.ph/average-life-expectancy-with-mesothelioma-06-26-3 https://tgraph.io/best-mEsOtHELiOMA-coMpensATIon-lawYerS-06-26-2 https://te.legra.ph/exposure-to-asbestos-and-mesothelioma-06-26-2 https://te.legra.ph/mESOTHELIOMA-lAWYERS-hOUSTON-tEXAS-06-26-4 https://telegra.ph/houston-mesothelioma-lawyers-06-26-2 https://telegra.ph/aSBESToS-MEsOtHElioMA-symPTOMS-06-26-2 https://tgraph.io/DOES-MESOTHELIOMA-CAUSE-BACK-PAIN-06-26-2 https://issuu.com/fritzjaadk/docs/easy_money_loans_for_bad_credit https://te.legra.ph/IS-MESOTHELIOMA-A-FORM-OF-LUNG-CANCER-06-26-2 https://te.legra.ph/Mesothelioma-Symptoms-Of-Jaw-Pain-06-26-4 https://te.legra.ph/malIgNaNt-meSotheliOma-pAThOloGY-oUtLiNeS-06-26-3 https://telegra.ph/mesothelioma-staging-symptoms-06-26-4 https://te.legra.ph/malignant-biphasic-mesothelioma-06-26-2 https://tgraph.io/benign-papillary-mesothelioma-pathology-06-26-3 https://telegra.ph/is-mesothelioma-non-small-cell-lung-cancer-06-26-4 https://telegra.ph/malignant-epithelioid-mesothelioma-treatments-06-26-3 https://telegra.ph/peritoneal-mesothelioma-cancer-survival-rate-06-26-4 https://issuu.com/jasonnwto/docs/get_money_fast_no_loans https://te.legra.ph/pericardial-mesothelioma-symptoms-06-26-4 https://te.legra.ph/bIPHASIC-mESOTHELIOMA-iCD-10-06-26-3 https://te.legra.ph/HOW-COMMON-IS-MESOTHELIOMA-06-26-2 https://telegra.ph/wHAT-iS-mALIGNANT-ePITHELIOID-mESOTHELIOMA-06-26-5 https://telegra.ph/epithelioid-malignant-peritoneal-mesothelioma-06-26-4 https://te.legra.ph/nON-sMALL-cELL-lUNG-cANCER-vS-mESOTHELIOMA-06-26-5 https://te.legra.ph/stage-2-mesothelioma-prognosis-06-26-5 https://te.legra.ph/malignant-pleural-mesothelioma-symptoms-06-26 https://te.legra.ph/stage-4-mesothelioma-life-expectancy-06-26-4 https://issuu.com/savoeunfqjqc/docs/get_money_fast_no_loans https://telegra.ph/Can-You-Get-Mesothelioma-From-06-26-2 https://telegra.ph/mesothelioma-death-symptoms-06-26-3 https://telegra.ph/ePitHeliAL-VarIAnt-mESOTheLiOMA-06-26-3 https://te.legra.ph/IS-mesothEliOmA-A-lunG-CANCer-06-26-4 https://tgraph.io/mALIGNANT-mESOTHELIOMA-pATHOLOGY-oUTLINES-06-26-2 https://telegra.ph/hOW-iS-mESOTHELIOMA-tRANSMITTED-06-26-3 https://te.legra.ph/mesothelioma-cancer-definition-06-26-2 https://te.legra.ph/Can-Mesothelioma-Cause-Back-Pain-06-26-2 https://te.legra.ph/can-mesothelioma-be-cured-if-caught-early-06-26-2 https://issuu.com/jasonnwto/docs/fast_money_loans_long_beach_ca https://te.legra.ph/what-is-malignant-pleural-mesothelioma-06-26-2 https://te.legra.ph/ePITHELIAL-mALIGNANT-mESOTHELIOMA-06-26-4 https://tgraph.io/BEniGN-MUlTiCYStIC-pERITONEAL-meSotheLiOma-06-26-2 https://telegra.ph/can-you-survive-pleural-mesothelioma-06-26-4 https://te.legra.ph/iS-mEsOtheLiOMa-MalIgnanT-06-26-5 https://te.legra.ph/MESOTHELIOMA-RARE-DISEASE-06-26-3 https://telegra.ph/wt1-mesothelioma-pathology-outlines-06-26-3 https://tgraph.io/is-mEsOTHELioMa-BeNIGN-OR-MalIGnant-06-26-2 https://tgraph.io/mesothelioma-workup-06-26-6 https://issuu.com/jasonnwto/docs/fast_money_loans https://tgraph.io/CANCER-DRUGS-FOR-MESOTHELIOMA-06-26-2 https://telegra.ph/How-To-Say-Mesothelioma-06-26-3 https://telegra.ph/Mesothelioma-Ford-Motor-Company-06-26-3 https://te.legra.ph/mesothelioma-cancer-ribbon-color-06-26-3 https://telegra.ph/perICArdIaL-MesOTheLIoMa-SYmptomS-06-26-5 https://te.legra.ph/biphasic-mesothelioma-flint-06-26-4 https://tgraph.io/mesothelioma-symptoms-latency-06-26-2 https://tgraph.io/how-do-you-treat-mesothelioma-06-26-2 https://telegra.ph/Is-Mesothelioma-Common-06-26-3 https://issuu.com/savoeunfqjqc/docs/money_payday_loans https://te.legra.ph/mesothelioma-benign-or-malignant-06-26-3 https://telegra.ph/mesothelioma-workup-06-26-3 https://telegra.ph/how-does-pleural-mesothelioma-affect-the-body-06-26-3 https://tgraph.io/epithelioid-mesothelioma-survival-rate-06-26-3 https://telegra.ph/biphasic-mesothelioma-flint-06-26-3 https://telegra.ph/mesothelioma-stage-iv-06-26-3 https://te.legra.ph/sarcomatoid-mesothelioma-diagnosis-06-26-5 https://telegra.ph/is-mesothelioma-caused-by-asbestos-06-26-3 https://te.legra.ph/how-to-say-mesothelioma-06-26-2 https://te.legra.ph/is-pleural-mesothelioma-cancer-06-26-4 https://te.legra.ph/Treatment-Of-Malignant-Mesothelioma-06-26-2 https://issuu.com/adamhyho/docs/fast_commercial_hard_money_loans https://te.legra.ph/is-mesoTHeLIoMA-a-TypE-of-LUnG-CANcEr-06-26-3 https://te.legra.ph/MALIGNANT-PLEURAL-MESOTHELIOMA-INCIDENCE-06-26-2 https://tgraph.io/stage-iv-mesothelioma-prognosis-06-26-2 https://te.legra.ph/how-do-you-know-if-you-have-mesothelioma-06-26-3 https://telegra.ph/hOW-lONG-cAN-i-lIVE-wITH-mESOTHELIOMA-06-26-2 https://te.legra.ph/IS-THERE-A-CURE-FOR-MESOTHELIOMA-CANCER-06-26-3 https://te.legra.ph/what-is-the-symptoms-of-mesothelioma-06-26-3 https://tgraph.io/abdominal-mesothelioma-symptoms-06-26-3 https://issuu.com/jasonnwto/docs/fast_money_loans_online https://te.legra.ph/lATE-sTAGE-mESOTHELIOMA-sYMPTOMS-06-26-3 https://telegra.ph/MALIGNANT-PLEURAL-MESOTHELIOMA-SYMPTOMS-06-26 https://telegra.ph/SYMPTOMS-OF-MESOTHELIOMA-IN-MEN-06-26-2 https://te.legra.ph/symptoms-of-abdominal-mesothelioma-06-26-2 https://tgraph.io/can-mESOthEliOMA-BE-CurEd-06-26-2 https://te.legra.ph/hOW-lONG-dOES-mESOTHELIOMA-lAST-06-26 https://tgraph.io/STAGE-4-MESOTHELIOMA-SYMPTOMS-06-26 https://issuu.com/jasonnwto/docs/fast_money_loans_near_me https://telegra.ph/Best-Mesothelioma-Law-Firm-06-26-2 https://te.legra.ph/does-asbestos-cause-mesothelioma-06-26-2 https://telegra.ph/how-to-cure-mesothelioma-naturally-06-26-3 https://te.legra.ph/MALIGnANT-MEsOTHelIOMa-CausES-06-26-4 https://telegra.ph/benign-papillary-mesothelioma-pathology-06-26-3 https://tgraph.io/wHat-is-malignANt-ePiTHELIOid-mesoTHelIoMa-06-26-6 https://tgraph.io/symptoms-of-mesothelioma-cancer-06-26-5 https://te.legra.ph/is-mesothelioma-always-malignant-06-26-2 https://te.legra.ph/BIolOGicAL-cANcEr-TrEAtmeNt-foR-MEsoThELiOmA-06-26-2 https://issuu.com/adamhyho/docs/fast_money_car_title_loans https://telegra.ph/mESOTHELIOMA-cANCER-aSBESTOS-06-26-3